Willingness to pay for diabetes drug therapy in type 2 diabetes patients: Based on LEAD clinical programme results

Journal of Medical Economics

Volumn 15, Issue SUPPL. 2, 2012, Pages 1-5

  Jendle, J ^a,b   Torffvit, O ^c   Ridderstrale M ^c,d   Ericsson, A ^e   Nilsen, B ^e   Bogelund, M ^f  

^a Karlstad Hospital   (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY   (Sweden)

^e Novo Nordisk Scandinavia   (Sweden)

^f Novo Nordisk Scandinavia ^*  (Denmark)

Author keywords

Discrete choice experiment; Liraglutide; Type 2 diabetes; Willingness to pay

Indexed keywords

EXENDIN 4; GLIMEPIRIDE; GLUCOSE; INSULIN GLARGINE; LIRAGLUTIDE; ROSIGLITAZONE;

ARTICLE; DIABETIC PATIENT; DRUG COST; DRUG EFFICACY; DRUG PREFERENCE; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; WEIGHT REDUCTION;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN, LONG-ACTING; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; VENOMS; WEIGHT LOSS;

EID: 84867939081     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.703633     Document Type: Article

References (29)

1. Hake C-M. Kontroll av blodsocker blir allt sämre-varför Diabetolognytt 2011;24:e-pub
2. Chiu CJ, Wray LA. Factors predicting glycemic control in middle-aged and older adults with type 2 diabetes. Prev Chronic Dis 2010;7:A08
3. Fakhoury WK, Lereun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 2010;86:44-57
4. Philippe J, Raccah D. Treating type 2 diabetes: how safe are current therapeutic agents? Int J Clin Pract 2009;63:321-32
5. Bøgelund M, Vilsbøll T, Henriksen JE, et al. Patient preferences for diabetes management among people with type 2 diabetes in Denmark-a discrete choice experiment. Curr Med Res Opin 2011;27:2175-83
6. Dranitsaris G, Longo CJ, Grossman LD. The economic value of a new insulin preparation, Humalog Mix 25. Measured by a willingness-to-pay approach. Pharmacoeconomics 2000;18:275-87
7. Jendle J, Torffvit O, Ridderstrale M, et al. Willingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetes. Curr Med Res Opin 2010;26:917-23
8. Lloyd A, Nafees B, Barnett AH, et al. Willingness to pay for improvements in chronic long-acting insulin therapy in individuals with type 1 or type 2 diabetes. Clin Ther 2011;33:1258-67
9. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47
10. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, doubleblind, parallel-treatment trial. Lancet 2009;373:473-81
11. Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-78
12. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84-90
13. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met +SU): a randomised controlled trial. Diabetologia 2009;52:2046-55
14. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met +TZD). Diabetes Care 2009;32:1224-30
15. Bogelund M, Vilsboll T, Faber J, et al. Patient preferences for diabetes management among people with type 2 diabetes in Denmark-a discrete choice experiment. Curr Med Res Opin 2011;27:2175-83
16. Jendle J, Nauck MA, Matthews DR, et al. Weight loss with liraglutide, a oncedaily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 2009;11:1163-72
17. Liu JT, Tsou MW, Hammitt JK. Willingness to pay for weight-control treatment. Health Policy 2009;91:211-8
18. Egede LE, Nietert PJ, Zheng D. Depression and all-cause and coronary heart disease mortality among adults with and without diabetes. Diabetes Care 2005;28:1339-45 (Pubitemid 40756694)
19. Jansen HJ, Vervoort G, van der Graaf M, et al. Pronounced weight gain in insulin-treated patients with type 2 diabetes mellitus is associated with an unfavourable cardiometabolic risk profile. Neth J Med 2010;68:359-66
20. Sjoberg N, Brinkworth GD, Wycherley TP, et al. Moderate weight loss improves heart rate variability in overweight and obese adults with type 2 diabetes. J Appl Physiol 2011;110:1060-4
21. Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011;34:1481-6
22. Feldstein AC, Nichols GA, Smith DH, et al. Weight change and glycemic control after diagnosis of type 2 diabetes. J Gen Intern Med 2008; 23:1339-45
23. Feldstein AC, Nichols GA, Smith DH, et al. Weight change in diabetes and glycemic and blood pressure control. Diabetes Care 2008;31:1960-5
24. Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003;22:331-9 (Pubitemid 37254901)
25. Gregg EW, Gerzoff RB, Thompson TJ, et al. Trying to lose weight, losing weight, and 9-year mortality in overweight U.S. adults with diabetes. Diabetes Care 2004;27:657-62 (Pubitemid 38280529)
26. Wolf AM, Siadaty M, Yaeger B, et al. Effects of lifestyle intervention on health care costs: Improving Control with Activity and Nutrition (ICAN). J Am Diet Assoc 2007;107:1365-73 (Pubitemid 47101767)
27. Yu AP, Wu EQ, Birnbaum HG, et al. Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. Curr Med Res Opin 2007;23:2157-69 (Pubitemid 350246602)
28. Louviere JJ, Timmermans HJP. Stated preference and choice models applied to recreation research: a review. Leisure Sci 1990;12:9-32
29. Ryan M, Watson V. Comparing welfare estimates from payment card contingent valuation and discrete choice experiments. Health Econ 2009; 18:389-401